These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 30453034)

  • 1. Can 14-3-3 proteins serve as therapeutic targets for the treatment of metabolic diseases?
    Diallo K; Oppong AK; Lim GE
    Pharmacol Res; 2019 Jan; 139():199-206. PubMed ID: 30453034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resveratrol in metabolic health: an overview of the current evidence and perspectives.
    Poulsen MM; Jørgensen JO; Jessen N; Richelsen B; Pedersen SB
    Ann N Y Acad Sci; 2013 Jul; 1290():74-82. PubMed ID: 23855468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Scaffold Proteins: From Coordinating Signaling Pathways to Metabolic Regulation.
    Mugabo Y; Lim GE
    Endocrinology; 2018 Nov; 159(11):3615-3630. PubMed ID: 30204866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacotherapeutic targeting of the endocannabinoid signaling system: drugs for obesity and the metabolic syndrome.
    Vemuri VK; Janero DR; Makriyannis A
    Physiol Behav; 2008 Mar; 93(4-5):671-86. PubMed ID: 18155257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GPR55: Metabolic Help or Hindrance?
    Henstridge CM; Brown AJ; Waldhoer M
    Trends Endocrinol Metab; 2016 Sep; 27(9):606-608. PubMed ID: 27215467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The 14-3-3 proteins in regulation of cellular metabolism.
    Kleppe R; Martinez A; Døskeland SO; Haavik J
    Semin Cell Dev Biol; 2011 Sep; 22(7):713-9. PubMed ID: 21888985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitochondrial dynamics, quality control and miRNA regulation in skeletal muscle: implications for obesity and related metabolic disease.
    Dahlmans D; Houzelle A; Schrauwen P; Hoeks J
    Clin Sci (Lond); 2016 Jun; 130(11):843-52. PubMed ID: 27129097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Overview of FGF19 and FGF21: The Therapeutic Role in the Treatment of the Metabolic Disorders and Obesity.
    Babaknejad N; Nayeri H; Hemmati R; Bahrami S; Esmaillzadeh A
    Horm Metab Res; 2018 Jun; 50(6):441-452. PubMed ID: 29883971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular mechanisms underlying the potential antiobesity-related diseases effect of cocoa polyphenols.
    Ali F; Ismail A; Kersten S
    Mol Nutr Food Res; 2014 Jan; 58(1):33-48. PubMed ID: 24259381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peroxisome proliferator-activated receptor gamma and metabolic disease.
    Willson TM; Lambert MH; Kliewer SA
    Annu Rev Biochem; 2001; 70():341-67. PubMed ID: 11395411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 14-3-3 zeta as novel molecular target for cancer therapy.
    Matta A; Siu KW; Ralhan R
    Expert Opin Ther Targets; 2012 May; 16(5):515-23. PubMed ID: 22512284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CIDE proteins and metabolic disorders.
    Gong J; Sun Z; Li P
    Curr Opin Lipidol; 2009 Apr; 20(2):121-6. PubMed ID: 19276890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypothalamic inflammation and malfunctioning glia in the pathophysiology of obesity and diabetes: Translational significance.
    Rahman MH; Bhusal A; Lee WH; Lee IK; Suk K
    Biochem Pharmacol; 2018 Jul; 153():123-133. PubMed ID: 29337002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Essential Element Manganese, Oxidative Stress, and Metabolic Diseases: Links and Interactions.
    Li L; Yang X
    Oxid Med Cell Longev; 2018; 2018():7580707. PubMed ID: 29849912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anhydroicaritin improves diet-induced obesity and hyperlipidemia and alleviates insulin resistance by suppressing SREBPs activation.
    Zheng ZG; Zhou YP; Zhang X; Thu PM; Xie ZS; Lu C; Pang T; Xue B; Xu DQ; Chen Y; Chen XW; Li HJ; Xu X
    Biochem Pharmacol; 2016 Dec; 122():42-61. PubMed ID: 27816546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting bile-acid signalling for metabolic diseases.
    Thomas C; Pellicciari R; Pruzanski M; Auwerx J; Schoonjans K
    Nat Rev Drug Discov; 2008 Aug; 7(8):678-93. PubMed ID: 18670431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological chaperones: potential treatment for conformational diseases.
    Bernier V; Lagacé M; Bichet DG; Bouvier M
    Trends Endocrinol Metab; 2004 Jul; 15(5):222-8. PubMed ID: 15223052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting endoplasmic reticulum stress in metabolic disease.
    Cao SS; Kaufman RJ
    Expert Opin Ther Targets; 2013 Apr; 17(4):437-48. PubMed ID: 23324104
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.